Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Receivables (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Change in Receivables for 6 consecutive years, with -$3.9 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 352.38% to -$3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Dec 2025, up 54.66% year-over-year, with the annual reading at $13.8 million for FY2025, 54.66% up from the prior year.
  • Change in Receivables hit -$3.9 million in Q4 2025 for Harmony Biosciences Holdings, down from $7.7 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $22.9 million in Q1 2025 to a low of -$13.0 million in Q2 2025.
  • Historically, Change in Receivables has averaged $3.7 million across 5 years, with a median of $3.4 million in 2022.
  • Biggest five-year swings in Change in Receivables: surged 2215.69% in 2023 and later plummeted 477.78% in 2025.
  • Year by year, Change in Receivables stood at $1.6 million in 2021, then plummeted by 119.85% to -$325000.0 in 2022, then soared by 2215.69% to $6.9 million in 2023, then crashed by 77.73% to $1.5 million in 2024, then tumbled by 352.38% to -$3.9 million in 2025.
  • Business Quant data shows Change in Receivables for HRMY at -$3.9 million in Q4 2025, $7.7 million in Q3 2025, and -$13.0 million in Q2 2025.